Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FluMist Picks Up Insurance Reimbursement, CDC Endorsement After Outbreak

Executive Summary

MedImmune/Wyeth's FluMist has picked up insurance company support with a series of announcements from payors that they will reimburse members receiving FluMist vaccines

You may also be interested in...



MedImmune FluMist Sales Of $30 Mil. Expected; 50% Return Rate Possible

MedImmune expects to record about $30 mil. of sales-related revenue for the FluMist nasal flu vaccine during the 2003-2004 launch season

MedImmune FluMist Sales Of $30 Mil. Expected; 50% Return Rate Possible

MedImmune expects to record about $30 mil. of sales-related revenue for the FluMist nasal flu vaccine during the 2003-2004 launch season

FluMist discounts for health departments

State and local health departments can purchase up to 3 mil. doses of FluMist at $20 a dose versus the usual price of $46 a dose. HHS negotiated the contract with Wyeth/MedImmune for health departments to meet increased demand for flu vaccines (1"The Pink Sheet" Dec. 15, 2003, p. 33). If all 3 mil. doses were sold, the contract would represent the majority of the 4-5 mil. doses manufactured this year. Wyeth/MedImmune had been offering $25 rebate coupons following many insurance companies' initial reluctance to cover the vaccine (2"The Pink Sheet" Nov. 17, 2003, p. 35)...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS042980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel